RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
Must read @FJDNefrologia
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 DM. Free access:➡️ https://t.co/22Pw53hEPC 😀@SVNefro @SENefrologia @secardiologia @sociedadSEEN @SEDiabetes @SEMERGENap @s
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2FPTIY
En pacientes con DM 2 el mensaje es claro. Además de mejorar la glicemia, optimizar y reducir el riesgo cardiovascular. https://t.co/DRdwtBl44r
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes https://t.co/ONIy9U7Qq2
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes vía @sociedadSEEN
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
Dm2 con IC, IRC o alto riesgo cardiovascular ➡️iSGLT2 y/o aGLP1
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/mbHlbeiMV8
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes https://t.co/6yAaI7GRbt
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in patients with Type 2 #Diabetes https://t.co/u6RCWtdMD6 via @ACCinTouch @JACCJournals https://t.co/jeRZzj34cQ
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2FPTIY
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/FaNHxoNTvD
RT @CynthiaJacksonP: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
RT @CynthiaJacksonP: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
RT @DavidACohen_MD: First major organization to recommend an GLP-1 agonist or SGLT2 Inhibitor as first line treatment over metformin for ma…
RT @CynthiaJacksonP: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
RT @DavidACohen_MD: First major organization to recommend an GLP-1 agonist or SGLT2 Inhibitor as first line treatment over metformin for ma…
RT @CynthiaJacksonP: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
RT @CynthiaJacksonP: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. https://t.co/p0jPsB9utv https://t.co/s5FyRkHCIA
RT @DrAdrianNaranjo: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
New ACC Guidance on CVD Risk Reduction in Diabetes https://t.co/H1tTL43ytk
RT @DrAdrianNaranjo: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
RT @DrAdrianNaranjo: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Di…
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes https://t.co/9FPNTi4lSH @JACCJournals
ACC is the first Organization to Recommend CV Benefical Rx (SGLT-2 Inhibitors and GLP-1 “Glutides”). https://t.co/uSGNubf2d5
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes https://t.co/PKKqGqc2QP
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes https://t.co/3lKvoHWV4Y
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
RT @HanCardiomd: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. https://t.co/dXMopE5V3u @ACCinTouch @JACCJournals
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…
RT @AmbrizMau: Aspectos importantes de los inhibidores de SGLT2 que han demostrado beneficio cardiovascular: JACC 2020; DOI: https://t.co/…